Discovery of a Potential Best-in-Class Anti-CD38 Therapeutic Utilizing Fc Multimerization

Time: 12:30 pm
day: Day Two


  • Momenta’s proprietary SIFbody technology offers a highly differentiated product scaffold; delivering optimal Fc effector function for effective cell depletion with the potential to induce long-term disease remission
  • Anti-CD38 SIFbody offers the potential to enhance immune cell and complement mediated cytotoxicity against disease causing plasma cells and tumor cells as compared to therapeutic anti-CD38 mAbs
  • In single and multiple dose studies in cynomolgus monkeys, anti-CD38 SIFbody demonstrated superior potency and durability in peripheral B cell and tissue plasma cell depletion than therapeutic anti-CD38 mAb